MetaCap

Medicus Pharma (MDCX) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MDCX+608.49%XBIO-36.65%
+2244%+1046%-151%
Oct 7, 20261 yearNov 20, 2026
MDCX+1132.36%XBIO-34.27%
+3602%+1697%-207%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MDCX versus XBIO key metrics
MetricMDCXXBIO
Share price$1.14$1.40
Market cap$3.16M$3.28M
1-day change-2.16%-9.09%
YTD return-25.82%—
1-year return-46.71%—
EPS (TTM)$-76.65$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.98M
Revenue growth (YoY)—+19.04%
Net income (latest FY)$-47.28M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$114.00$4.94
52-week low$1.06$1.25
Distance from 52-week high-99.00%-71.65%
Analyst consensusnone—
Avg. price target upside+296.48%—
Average volume116.55K73.30K
Shares outstanding2.79M2.34M
Employees162
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Medicus Pharma

MDCX stock →

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

MDCX vs XBIO FAQ

Which is bigger, Medicus Pharma or Xenetic Biosciences?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.16M for Medicus Pharma (MDCX).

Are Medicus Pharma and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons